NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the quarter ended June 30, 2009 and provided an update on the Company’s clinical programs following the Company’s presentations at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.
